NVO Novo Nordisk A/S ADRs
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark. This is an ADR of a company whose stock trades outside of the U.S. as the symbol DC:NOVO-B.
$154.94 +2.19 (1.43%)
As of 03/27/2023 13:57:33 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Large cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Denmark
Country of incorporation: Denmark
IPO date: 09/05/2001
Outstanding shares: 1,742,564,000
Average volume: 1,565,762
Market cap: $260,652,723,120
Current dividend yield: 1.07%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%